Franklin Biotechnology Discovery Fund C (FBTDX)
163.82
+1.16
(+0.71%)
USD |
Dec 04 2025
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.77% | 954.14M | 0.41% | 22.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -134.42M | 41.68% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks to provide capital appreciation. Under normal market conditions, the Fund predominantly invests in equity securities and invests at least 80% of its net assets in securities of biotechnology companies(at least 50% of its earnings derived from biotechnology activities) and discovery research firms. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Franklin Templeton |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
49
-129.73M
Peer Group Low
1.550B
Peer Group High
1 Year
% Rank:
63
-134.42M
-3.013B
Peer Group Low
514.53M
Peer Group High
3 Months
% Rank:
70
-537.77M
Peer Group Low
1.698B
Peer Group High
3 Years
% Rank:
62
-8.541B
Peer Group Low
312.13M
Peer Group High
6 Months
% Rank:
65
-1.345B
Peer Group Low
1.449B
Peer Group High
5 Years
% Rank:
71
-7.624B
Peer Group Low
2.983B
Peer Group High
YTD
% Rank:
64
-2.538B
Peer Group Low
561.96M
Peer Group High
10 Years
% Rank:
73
-13.08B
Peer Group Low
5.532B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of December 05, 2025.
Asset Allocation
As of October 31, 2025.
| Type | % Net |
|---|---|
| Cash | -0.25% |
| Stock | 95.43% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 0.72% |
| Other | 4.09% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Gilead Sciences, Inc. | 5.57% | 121.24 | -1.12% |
| Vertex Pharmaceuticals, Inc. | 4.56% | 455.50 | -0.41% |
| Amgen, Inc. | 4.49% | 329.83 | -3.04% |
| Franklin Institutional US Government Money Mrkt Fd | 4.19% | 1.00 | 0.00% |
| argenx SE | 4.14% | 901.18 | -1.61% |
| Regeneron Pharmaceuticals, Inc. | 4.09% | 718.27 | -0.63% |
| Jazz Pharmaceuticals Plc | 4.02% | 169.69 | 1.67% |
| Alnylam Pharmaceuticals, Inc. | 3.83% | 457.98 | -1.58% |
| Insmed, Inc. | 3.75% | 203.96 | -0.53% |
| Praxis Precision Medicines, Inc. | 3.08% | 247.84 | 30.47% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 1.00% |
| Actual Management Fee | 0.60% |
| Administration Fee | -- |
| Maximum Front Load | 0.00% |
| Maximum Deferred Load | 1.00% |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 1000.00 None |
| Minimum Subsequent Investment | 0.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks to provide capital appreciation. Under normal market conditions, the Fund predominantly invests in equity securities and invests at least 80% of its net assets in securities of biotechnology companies(at least 50% of its earnings derived from biotechnology activities) and discovery research firms. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Franklin Templeton |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (12-3-25) | 0.79% |
| 30-Day SEC Yield (3-31-23) | -1.07% |
| 7-Day SEC Yield | -- |
| Number of Holdings | 10 |
| Stock | |
| Weighted Average PE Ratio | 28.05 |
| Weighted Average Price to Sales Ratio | 18.13 |
| Weighted Average Price to Book Ratio | 10.14 |
| Weighted Median ROE | -172.8% |
| Weighted Median ROA | -20.81% |
| ROI (TTM) | -47.44% |
| Return on Investment (TTM) | -47.44% |
| Earning Yield | 0.0482 |
| LT Debt / Shareholders Equity | 2.899 |
| Number of Equity Holdings | 9 |
As of October 31, 2025
Growth Metrics
| EPS Growth (1Y) | 5.44% |
| EPS Growth (3Y) | -0.21% |
| EPS Growth (5Y) | 7.24% |
| Sales Growth (1Y) | 27.10% |
| Sales Growth (3Y) | 19.36% |
| Sales Growth (5Y) | 30.89% |
| Sales per Share Growth (1Y) | 3.26K% |
| Sales per Share Growth (3Y) | 15.64% |
| Operating Cash Flow - Growth Rate (3Y) | 7.00% |
As of October 31, 2025
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:FBTDX", "name") |
| Broad Asset Class: =YCI("M:FBTDX", "broad_asset_class") |
| Broad Category: =YCI("M:FBTDX", "broad_category_group") |
| Prospectus Objective: =YCI("M:FBTDX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |